Melvin Lafeber

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis et al. · New England Journal of Medicine · 2022 · 125 citations · Full text

Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET): an international, multicentre, retrospective, observational cohort study

Roos S. G. Sablerolles, Melvin Lafeber, Janneke A. L. van Kempen et al. · The Lancet Healthy Longevity · 2021 · 109 citations · Full text

Geriatrics, Medicine, Global Health +12

Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial

Melvin Lafeber, Diederick E. Grobbee, Ilse M. Schrover et al. · International Journal of Cardiology · 2014 · 62 citations

Hypertension, Cardiovascular Disease, Crossover Trial +7

The combined use of aspirin, a statin, and blood pressure–lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease

Melvin Lafeber, Wilko Spiering, Yolanda van der Graaf et al. · American Heart Journal · 2013 · 56 citations

Thrombosis, Hypertension, Blood Pressure–lowering Agents +11

Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline

Melvin Lafeber, Aline M.E. Stades, Gerlof D. Valk et al. · European Journal of Endocrinology · 2010 · 52 citations · Full text